Hormone Therapy for Breast Cancer Hagerstown MD

Breast tenderness in women taking estrogen/progestin hormone replacement therapy could signal increased chances of developing breast cancer, a new study says. Women in Hagerstown taking estrogen plus progestin who reported developing breast tenderness after starting the hormone therapy were 48 percent more likely to develop invasive breast cancer than women on hormone therapy who did not experience breast tenderness.

Hind Hamdan, MD
(301) 797-8279
1130 Opal Ct
Hagerstown, MD
Specialties
Oncology (Cancer), Internal Medicine
Gender
Female
Languages
Arabic
Education
Medical School: American Univ Of Beirut, Fac Of Med, Beirut, Lebanon
Graduation Year: 1985
Hospital
Hospital: Washington County Hospital, Hagerstown, Md

Data Provided by:
Dr.Hind Hamdan
(301) 797-8279
1130 Opal Court
Hagerstown, MD
Gender
F
Education
Medical School: American Univ Of Beirut, Fac Of Med, Beirut
Year of Graduation: 1985
Speciality
Oncologist
General Information
Hospital: Washington County Hospital, Hagerstown, Md
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 3, reviews.

Data Provided by:
Michael Joseph Mc Cormack, MD
(301) 733-8600
11110 Medical Campus Rd Ste 130
Hagerstown, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1982

Data Provided by:
Dan Roger Cornell, MD
(301) 665-4650
11110 Medical Campus Rd Ste 129
Hagerstown, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1987

Data Provided by:
Robert Kent Finley
(717) 762-7155
45 Roadside Ave
Waynesboro, PA
Specialty
General Surgery, Surgical Oncology

Data Provided by:
Alida Mercedes Espinoza
(301) 797-8279
1130 Opal Ct
Hagerstown, MD
Specialty
Hematology / Oncology

Data Provided by:
Michael J McCormack
(301) 733-8600
11110 Medical Campus Rd
Hagerstown, MD
Specialty
Internal Medicine, Medical Oncology

Data Provided by:
Frederic Henry Kass III, MD
(301) 733-8607
11110 Medical Campus Rd Ste 130
Hagerstown, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: George Washington Univ Sch Of Med & Hlth Sci, Washington Dc 20037
Graduation Year: 1974

Data Provided by:
Gerald Stephen Brown, MD
(301) 824-3343
22911 Jefferson Blvd
Smithsburg, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Univ Of Ottawa, Fac Of Med, Ottawa, Ont, Canada
Graduation Year: 1963

Data Provided by:
Kanan H Hudhud
(301) 695-6777
46b Thomas Johnson Dr
Frederick, MD
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Data Provided by:

Hormone Therapy for Breast Cancer

Provided By:

MONDAY, Oct. 12 (HealthDay News) -- Breast tenderness in women taking estrogen/progestin hormone replacement therapy could signal increased chances of developing breast cancer, a new study says.

Women taking estrogen plus progestin who reported developing breast tenderness after starting the hormone therapy were 48 percent more likely to develop invasive breast cancer than women on hormone therapy who did not experience breast tenderness.

Researchers said more study is needed before they would recommend that women who experience this symptom discontinue taking the hormones. But women who develop breast tenderness might want to reassess if the hormones are really necessary to control their menopausal symptoms.

"It's too soon to tell women to quit their hormone therapy, but it is something for women to think about in balancing the risks versus the benefits," said the study's lead author, Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and health services research at the David Geffen School of Medicine at the University of California, Los Angeles.

"Breast tenderness is a symptom that may be a risk marker for breast cancer," she said.

The study is in the Oct. 12 issue of the Archives of Internal Medicine.

Researchers used data from the Women's Health Initiative, a landmark federal study that was halted in 2002 after investigators determined that hormone replacement therapy increased the risk for heart attack, stroke and invasive breast cancer.

Since then, most women have been advised to use hormone replacement therapy -- which physicians now call menopausal hormone therapy -- either not at all or for the shortest duration possible to get them through their most uncomfortable menopausal symptoms, usually hot flashes, Crandall said. Women are strongly advised to avoid taking hormones for longer than five years, when the risk for breast cancer doubles.

In the new study, more than 8,500 women took estrogen plus progestin, and more than 8,100 took a placebo. Participants were given a mammogram and breast exam at the start of the trial and annually thereafter.

At the one-year mark, women on the combination therapy were three times more likely to report experiencing breast tenderness than women on the placebo. About 36 percent of women on the hormone therapy reported new breast tenderness, compared with nearly 12 percent of women on a placebo.

During 5.6 years of follow-up, 0.6 percent of women who reported new breast tenderness were diagnosed with breast cancer each year, compared with 0.36 percent of women taking hormones who did not experience new breast tenderness.

Researchers aren't certain why some women on hormone therapy develop breast cancer while others don't, though the breast tenderness may provide a clue, Crandall said. Tenderness could be a sign that the cells of the breast are multiplying rapidly. Cell proliferation is a risk factor for cancer.

Mary B. Daly, director of the Personalized Cancer Risk Assessment Program at Fox Chase Cancer Center in Philadelphia, said the findings of the study, which she described as well done, should prompt women and their doctors to reassess the need for hormone replacement if such tenderness develops.

Yet individual differences -- why this happens to some women and not others -- are still not well understood, Daly said.

"Some women who start taking hormone therapy may have cells that are much more receptive to it, or more sensitive to it, while other women must be more resistant," Daly said. "Something must be different about the breast tissue to make it more or less responsive to the hormones. If we could figure that out, that would be great."

Women in the study were taking daily doses of oral conjugated equine estrogens (0.625 milligrams) plus medroxyprogesterone acetate (2.5 milligrams).

The findings apply only to women taking the combination therapy, not women who've had hysterectomies and are taking estrogen alone, Crandall said.

In a statement, Wyeth Pharmaceuticals, which makes the estrogen-progestin therapy Prempro, called the study "interesting" but added that, "breast tenderness is not an established risk factor for breast cancer." According to the company, up to a quarter of women who take combination hormone therapy will develop some tenderness in the breast, typically transient. The company also noted that the "small" increase in breast cancer risk for women on combo therapy and those on placebo, "has previously been reported and is included in the Prescribing Information (labeling) for Prempro."

More information

The U.S. National Heart, Lung and Blood Institute has more on menopausal hormone therapy.

SOURCES: Carolyn Crandall, M.D., clinical professor, general internal medicine and health services research, David Geffen School of Medicine, University of California, Los Angeles, and faculty member, Iris Cantor-UCLA Women's Health Center; Mary B. Daly, M.D., Ph.D., director, Personalized Cancer Risk Assessment Program, Fox Chase Cancer Center, Philadelphia; Oct. 12, 2009, news statement, Wyeth Pharmaceuticals; Oct. 12, 2009, Archives of Internal Medicine

Author: By Jennifer Thomas
HealthDay Reporter

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com